Barr to Challenge Patents Protecting Prefest Hormone Therapy

Law360, New York (December 4, 2003, 12:00 AM EST) -- Generic drugmaker Barr Laboratories said Thursday it is challenging the patents protecting King Pharmaceutical's Prefest hormone therapy.

Each Prefest tablet contains 1 mg estradiol alone or 1 mg estradiol and 0.09 mg norgestimate, and is indicated in women with an intact uterus for the treatment of moderate to severe menopausal symptoms.

Barr filed an Abbreviated New Drug Application for Prefest with the Food and Drug Administration in August 2003, and received notification of the application's acceptance in September 2003. Barr notified King and Jencap Research, Ltd.,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.